Therapeutic Goods (Charges) Amendment Bill 2026
UnknownSummary
The Therapeutic Goods Administration currently charges fees to companies that want to register medicines, medical devices, and other health products in Australia. This amendment changes how those charges work — adjusting the fees that manufacturers and importers must pay when they submit products for approval or renewal. The changes affect anyone bringing therapeutic goods to market in Australia, from large pharmaceutical companies to smaller health product businesses, and may alter the cost of bringing new treatments to Australian patients by making the registration process more or less expensive depending on the product type.
Bill Progress
Senate
First Reading
Second Reading
Committee of the Whole
Third Reading
House of Representatives
First Reading
Second Reading
Consideration in Detail
Third Reading
Royal Assent
Royal Assent